Table 1.
Baseline characteristics of subjects—cerebrospinal fluid analysis.
| Overall sample (N = 64) |
SSD (n = 32) |
Healthy volunteers (n = 32) |
p value | |
|---|---|---|---|---|
| Age, mean (SD) | 38.5 (11.6) | 36.1 (12.4) | 41.0 (10.3) | 0.09 |
| Male sex, n (%) | 45 (70.3) | 25 (78.1) | 20 (62.5) | 0.17 |
| Non-hispanic ethnicity, n (%) [sample size] | 30 (85.7) [35] | 11 (78.6) [14] | 19 (90.5) [21] | 0.3 |
| Race | 0.56 | |||
| Black, n (%) | 28 (43.8) | 15 (46.9) | 13 (40.6) | |
| White, n (%) | 21 (31.3) | 8 (25.0) | 13 (40.6) | |
| Other, n (%) | 15 (22.4) | 9 (25.7) | 6 (18.8) | |
| Diagnosis | NA | |||
| Schizophrenia, n (%) | NA | 19 (59.4) | NA | |
| Schizoaffective disorder, n (%) | NA | 10 (31.3) | NA | |
| Psychosis NOS, n (%) | NA | 3 (9.4) | NA | |
| BPRS score, mean (SD) | NA | 29.8 (8.6) [29] | NA | NA |
| Number of hospitalizations, median (IQR) | 5 (2–8.5) [20] | NA | NA | |
| Length of illness, median years (IQR) | NA | 14.0 (3.1–25.7) [21] | NA | NA |
| Medications | ||||
| Antipsychotics, n (%) | NA | 27 (100) [27] | NA | NA |
| Antidepressants, n (%) | NA | 12 (44.4) [27] | NA | NA |
| Mood stabilizers, n (%) | NA | 4 (14.8) [27] | NA | NA |
| Benzodiazepines, n (%) | NA | 8 (29.6) [27] | NA | NA |
| THC + in Utox, n (%) | 4 (6.5) [62] | 4 (13.3) [30] | 0 [30] | 0.03 |
| BMI, mean (SD) | 27.5 (5.7) [57] | 29.2 (7.1) [28] | 25.9 (3.3) [29] | 0.03 |
| MCCB composite score, mean (SD) | 35.6 (16.2) [60] | 25.9 (15.2) [30] | 45.4 (10.4) [30] | <0.0001 |
NOS not otherwise specified, BPRS Brief Psychiatric Rating Scale, THC tetrahydrocannabinol, Utox urine toxicology test, BMI body mass index, MCCB Matrics Consensus Cognitive Battery.
[ ]: number of subjects if different from group sample size.